ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2631

Validation of Clinically Relevant Improvement in Children and Adolescents with cSLE

Pinar Ozge Avar Aydin1, Michael J. Holland2, Simone Appenzeller3, Stacy P. Ardoin4, Tadej Avcin5, Michael W. Beresford6, Brian M. Feldman7, Francisco Flores8, Marisa S. Klein-Gitelman9, Beatrice Goilav10, Raju Khubchandani11, Deborah M. Levy12, Angelo Ravelli13, Nicolino Ruperto14, Clovis A Silva15, Scott E. Wenderfer16, Jun Ying17 and Hermine I. Brunner1, 1Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Pediatric Rheumatology Unit, State University of Campinas, Campinas, Brazil, 4Pediatric & Adult Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 5Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, 6On Behalf of the UK JSLE Study Group, Liverpool, United Kingdom, 7Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 8Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Division of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/Northwestern University, Chicago, IL, 10Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, 11Department of Paediatrics, Jaslok Hospital and Research Center, Mumbai, India, 12Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 13University of Genova, IRCCS Istituto Giannina Gaslini, Genova, Italy, 14Istituto Giannina Gaslini, Genoa, Italy, 15Rheumatology Unit, Instituto da Criança, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, 16Nephrology, Baylor College of Medicine, Texas Children's Hospital, houston, TX, 17Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a multisystem autoimmune disease that is characterized by episodes of flares followed by improvement in response to therapy. To assess the clinically relevant response and the efficiency of therapies in cSLE, sensitive and well-correlated criteria with changes in improvement are needed.

Objective: To prospectively validate the PRINTO/ACR Criteria of Response to Therapy (PCI) & assess their ability to capture clinically relevant improvement (CRI).

Methods: Consensus formation methodology (Delphi, nominal group technique; 77 % consensus level) was used to newly define CRI. Using prospective cSLE data, patient profiles (PPs) were developed which provided information at a baseline & follow-up visit, including the cSLE core response variables [CRVs: SLEDAI, the urinary protein-creatinine ratio (PCR), physician global assessments of cSLE disease activity, patient global assessment of well-being, quality of life score]. Twelve experts (>10 yrs experience managing cSLE) were asked to rate disease courses of up to 200 PPs using 2 scales: (1) no change/worsening, minor, moderate, or major improvement; and (2) clinically relevant improved, yes/no. Each PP was determined of the “true” course based upon the majority opinion of the raters. Multinomial logistic regression models (MLRs) were used to predict the true course and develop algorithms to calculate the continuous “improvement score” using absolute or percentage changes of the CRVs. ROC curves were analyzed for the MLR algorithms and AUC, specificity, sensitivity, and kappa statistics were calculated to assess the improvement scores for accuracy. Results were reviewed by the expert panel for further discussion and recommendation.

Results: The consensus definition of CRI was: “A clinically relevant improvement has occurred in a child with lupus if there are reduced signs of disease from active lupus. Although there may not be an improvement of lupus activity in all organ systems, there cannot be increased lupus activity in major organ systems (neuropsychiatric, hematological, gastrointestinal, renal, ophthalmological, and cardiopulmonary). Patient symptoms must be at least stable, and immunosuppressive therapy should be unchanged or decreased“ (100 % consensus). All 4 top PCI were highly sensitive and moderately accurate but specificity was lacking to various degrees of improvement or CRI. The MLR-based algorithms appeared more accurate than the PCI for CRI and minor/moderate/major improvement (Table 1).

Conclusion: The PCI are moderately accurate in this validation data set, but the MLR-derived criteria considering absolute CRV changes perform better in capturing CRI and cSLE improvement in general. If confirmed in larger validation studies, MLR-based algorithms may allow for a more effective assessment of response to therapy in cSLE.

 

Table 1. Multivariate Models for Improvement Criteria


Disclosure: P. O. Avar Aydin, None; M. J. Holland, None; S. Appenzeller, None; S. P. Ardoin, not applicable, 9; T. Avcin, None; M. W. Beresford, None; B. M. Feldman, None; F. Flores, None; M. S. Klein-Gitelman, Janssen Pharmaceutica Product, L.P., 2,Pfizer Inc, 2,UCB biosciences, 2,Abbvie, 2,Lupus Foundation of America, 2,NIH/LFA/Cure JM/Arthritis Foundation, 2,Up to Date, 7; B. Goilav, None; R. Khubchandani, None; D. M. Levy, None; A. Ravelli, None; N. Ruperto, BMS, Hoffman-La Roche, Janssen, Novartis, Pfizer and Sobi, 2,Abbvie, Ablynx, AstraZeneca, Baxalta Biosimilars, Biogen Idec, Boehringer, Bristol Myers Squibb, Eli-Lilly, EMD Serono, Gilead Sciences, Janssen, Medimmune, Novartis, Pfizer, Rpharm, Roche, Sanofi., 5,Abbvie, Ablynx, AstraZeneca, Baxalta Biosimilars, Biogen Idec, Boehringer, Bristol Myers Squibb, Eli-Lilly, EMD Serono, Gilead Sciences, Janssen, Medimmune, Novartis, Pfizer, Rpharm, Roche, Sanofi., 8; C. A. Silva, None; S. E. Wenderfer, None; J. Ying, None; H. I. Brunner, None.

To cite this abstract in AMA style:

Avar Aydin PO, Holland MJ, Appenzeller S, Ardoin SP, Avcin T, Beresford MW, Feldman BM, Flores F, Klein-Gitelman MS, Goilav B, Khubchandani R, Levy DM, Ravelli A, Ruperto N, Silva CA, Wenderfer SE, Ying J, Brunner HI. Validation of Clinically Relevant Improvement in Children and Adolescents with cSLE [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/validation-of-clinically-relevant-improvement-in-children-and-adolescents-with-csle/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-clinically-relevant-improvement-in-children-and-adolescents-with-csle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology